Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib

JAMA Oncol. 2020 Jun 1;6(6):927-929. doi: 10.1001/jamaoncol.2020.0571.

Abstract

This secondary analysis of data from the HERACLES-A clinical trial examines long-term outcomes in 32 patients with colorectal cancer treated with trastuzumab and lapatinib.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Central Nervous System Neoplasms / radiotherapy
  • Central Nervous System Neoplasms / secondary*
  • Central Nervous System Neoplasms / surgery
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / metabolism
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology
  • Drug Resistance, Neoplasm
  • Erb-b2 Receptor Tyrosine Kinases / metabolism*
  • Female
  • Humans
  • Lapatinib / therapeutic use*
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / therapeutic use*
  • Recurrence
  • Trastuzumab / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Lapatinib
  • Protein Kinase Inhibitors
  • Erb-b2 Receptor Tyrosine Kinases
  • Trastuzumab
  • ERBB2 protein, human